标题：Aminopeptidase N (EC 22.214.171.124) inhibitors (2006 - 2010): a patent review
作者：Li Su;Hao Fang;Wenfang Xu
作者机构：[Su, L] Shandong University, School of Pharmaceutical Sciences, Department of Medicinal Chemistry, 44 West Culture Road, 250012 Ji'nan, Shandong, Chin 更多
通讯作者地址：[Xu, WF]Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, 44 W Culture Rd, Jinan 250012, Shandong, Peoples R China.
来源：Expert opinion on therapeutic patents
关键词：aminopeptidase N;analgesia;angiogenesis;bestatin;degradation;dual inhibition;enkephalin;enzyme activity;inhibitor;invasion;neutral endopeptidase;selectivity;tumor;ZBG
摘要：Introduction: Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. Areas covered: In this review, APN inhibitors in the patents publicized during 2006 - 2010 are introduced. Readers will gain information on the patent inhibitors, including chemical structures, original sources or synthetic methods, biological assays and application potential. Expert opinion: It is difficult to identify compounds that interact with the function not relevant with peptide-hydrolysis of APN in the enzyme activity assay, and such compounds have not been reported in the patents during the past 5 years. The progress of protein-small molecule interaction detecting means, such as surface plasmon resonance, will possibly help develop such compounds for the treatment of relevant diseases or new molecular probes in mechanism investigation.